1
|
Mammoliti O, Jansen K, El Bkassiny S, Palisse A, Triballeau N, Bucher D, Allart B, Jaunet A, Tricarico G, De Wachter M, Menet C, Blanc J, Letfus V, Rupčić R, Šmehil M, Poljak T, Coornaert B, Sonck K, Duys I, Waeckel L, Lecru L, Marsais F, Jagerschmidt C, Auberval M, Pujuguet P, Oste L, Borgonovi M, Wakselman E, Christophe T, Houvenaghel N, Jans M, Heckmann B, Sanière L, Brys R. Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases. J Med Chem 2021; 64:14557-14586. [PMID: 34581584 DOI: 10.1021/acs.jmedchem.1c01066] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Current treatments only slow down disease progression, making new therapeutic strategies compelling. Increasing evidence suggests that S1P2 antagonists could be effective agents against fibrotic diseases. Our compound collection was mined for molecules possessing substructure features associated with S1P2 activity. The weakly potent indole hit 6 evolved into a potent phthalazone series, bearing a carboxylic acid, with the aid of a homology model. Suboptimal pharmacokinetics of a benzimidazole subseries were improved by modifications targeting potential interactions with transporters, based on concepts deriving from the extended clearance classification system (ECCS). Scaffold hopping, as a part of a chemical enablement strategy, permitted the rapid exploration of the position adjacent to the carboxylic acid. Compound 38, with good pharmacokinetics and in vitro potency, was efficacious at 10 mg/kg BID in three different in vivo mouse models of fibrotic diseases in a therapeutic setting.
Collapse
Affiliation(s)
- Oscar Mammoliti
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Koen Jansen
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Adeline Palisse
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Denis Bucher
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Brigitte Allart
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Alex Jaunet
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Maxim De Wachter
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Christel Menet
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Javier Blanc
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Vatroslav Letfus
- Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia
| | - Renata Rupčić
- Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia
| | - Mario Šmehil
- Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia
| | - Tanja Poljak
- Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia
| | | | - Kathleen Sonck
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Inge Duys
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Ludovic Waeckel
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Lola Lecru
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Florence Marsais
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | | | - Marielle Auberval
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Philippe Pujuguet
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Line Oste
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Monica Borgonovi
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | | | | | | | - Mia Jans
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Bertrand Heckmann
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Laurent Sanière
- Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France
| | - Reginald Brys
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| |
Collapse
|
2
|
Brebion F, Gosmini R, Deprez P, Varin M, Peixoto C, Alvey L, Jary H, Bienvenu N, Triballeau N, Blanque R, Cottereaux C, Christophe T, Vandervoort N, Mollat P, Touitou R, Leonard P, De Ceuninck F, Botez I, Monjardet A, van der Aar E, Amantini D. Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis. J Med Chem 2021; 64:2937-2952. [PMID: 33719441 DOI: 10.1021/acs.jmedchem.0c02008] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
There are currently no approved disease-modifying osteoarthritis (OA) drugs (DMOADs). The aggrecanase ADAMTS-5 is key in the degradation of human aggrecan (AGC), a component of cartilage. Therefore, ADAMTS-5 is a promising target for the identification of DMOADs. We describe the discovery of GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor obtained by optimization of a promising hydantoin series following an HTS. Biochemical activity against rat and human ADAMTS-5 was assessed via a fluorescence-based assay. ADAMTS-5 inhibitory activity was confirmed with human aggrecan using an AGC ELISA. The most promising compounds were selected based on reduction of glycosaminoglycan release after interleukin-1 stimulation in mouse cartilage explants and led to the discovery of GLPG1972/S201086. The anticatabolic activity was confirmed in mouse cartilage explants (IC50 < 1.5 μM). The cocrystal structure of GLPG1972/S201086 with human recombinant ADAMTS-5 is discussed. GLPG1972/S201086 has been investigated in a phase 2 clinical study in patients with knee OA (NCT03595618).
Collapse
Affiliation(s)
- Franck Brebion
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Romain Gosmini
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Pierre Deprez
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Marie Varin
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Luke Alvey
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Hélène Jary
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Natacha Bienvenu
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Roland Blanque
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Céline Cottereaux
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Nele Vandervoort
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Patrick Mollat
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Robert Touitou
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Philip Leonard
- Structural Biology, Charles River, Chesterford Research Park, CB10 1XL Saffron Walden, United Kingdom
| | - Frédéric De Ceuninck
- Institut de Recherches Servier, Center for Therapeutic Innovation, Immuno-inflammatory Disease, 78290 Croissy sur Seine, France
| | - Iuliana Botez
- Institut de Recherches Servier, Chemistry Center of Excellence, 78290 Croissy sur Seine, France
| | - Alain Monjardet
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - David Amantini
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
3
|
Joncour A, Desroy N, Housseman C, Bock X, Bienvenu N, Cherel L, Labeguere V, Peixoto C, Annoot D, Lepissier L, Heiermann J, Hengeveld WJ, Pilzak G, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Galien R, David C, Vandervoort N, Christophe T, Conrath K, Jans M, Wohlkonig A, Soror S, Steyaert J, Touitou R, Fleury D, Vercheval L, Mollat P, Triballeau N, van der Aar E, Brys R, Heckmann B. Correction to Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2- a]pyridine Series of Autotaxin Inhibitors. J Med Chem 2018; 61:4270. [DOI: 10.1021/acs.jmedchem.8b00579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Affiliation(s)
- Denis Bucher
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Pieter Stouten
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | |
Collapse
|
5
|
Joncour A, Desroy N, Housseman C, Bock X, Bienvenu N, Cherel L, Labeguere V, Peixoto C, Annoot D, Lepissier L, Heiermann J, Hengeveld WJ, Pilzak G, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Galien R, David C, Vandervoort N, Christophe T, Conrath K, Jans M, Wohlkonig A, Soror S, Steyaert J, Touitou R, Fleury D, Vercheval L, Mollat P, Triballeau N, van der Aar E, Brys R, Heckmann B. Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors. J Med Chem 2017; 60:7371-7392. [DOI: 10.1021/acs.jmedchem.7b00647] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Agnès Joncour
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Nicolas Desroy
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | | | - Xavier Bock
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Natacha Bienvenu
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Laëtitia Cherel
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | | | | | - Denis Annoot
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Luce Lepissier
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Jörg Heiermann
- Mercachem, Kerkenbos 1013, 6546 Nijmegen, The Netherlands
| | | | - Gregor Pilzak
- Mercachem, Kerkenbos 1013, 6546 Nijmegen, The Netherlands
| | - Alain Monjardet
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | | | | | | | - René Galien
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Christelle David
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Nele Vandervoort
- Galapagos NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | | | - Katja Conrath
- Galapagos NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Mia Jans
- Galapagos NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Alexandre Wohlkonig
- VIB
Structural Biology Research Center, Vrije Universiteit Brussel, 1050 Brussel, Belgium
| | - Sameh Soror
- VIB
Structural Biology Research Center, Vrije Universiteit Brussel, 1050 Brussel, Belgium
| | - Jan Steyaert
- VIB
Structural Biology Research Center, Vrije Universiteit Brussel, 1050 Brussel, Belgium
| | - Robert Touitou
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Damien Fleury
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Lionel Vercheval
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | - Patrick Mollat
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| | | | | | - Reginald Brys
- Galapagos NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Bertrand Heckmann
- Galapagos SASU, 102 Avenue Gaston
Roussel, 93230 Romainville, France
| |
Collapse
|
6
|
Desroy N, Housseman C, Bock X, Joncour A, Bienvenu N, Cherel L, Labeguere V, Rondet E, Peixoto C, Grassot JM, Picolet O, Annoot D, Triballeau N, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Blanque R, Cottereaux C, Vandervoort N, Christophe T, Mollat P, Lamers M, Auberval M, Hrvacic B, Ralic J, Oste L, van der Aar E, Brys R, Heckmann B. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem 2017; 60:3580-3590. [PMID: 28414242 DOI: 10.1021/acs.jmedchem.7b00032] [Citation(s) in RCA: 100] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disease areas including pulmonary fibrosis. Structural modifications of the known autotaxin inhibitor lead compound 1, to attenuate hERG inhibition, remove CYP3A4 time-dependent inhibition, and improve pharmacokinetic properties, led to the identification of clinical candidate GLPG1690 (11). Compound 11 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficacious in a bleomycin-induced pulmonary fibrosis model in mice and in reducing extracellular matrix deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid. Compound 11 is currently being evaluated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.
Collapse
Affiliation(s)
- Nicolas Desroy
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Xavier Bock
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Agnès Joncour
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Natacha Bienvenu
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Laëtitia Cherel
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Emilie Rondet
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | - Olivier Picolet
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Denis Annoot
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Alain Monjardet
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | | | - Roland Blanque
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Celine Cottereaux
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Nele Vandervoort
- Galapagos NV , Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Patrick Mollat
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Marieke Lamers
- Charles River Laboratories , Chesterford Research Park, CB10 1XL Saffron Walden, United Kingdom
| | - Marielle Auberval
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Boska Hrvacic
- Fidelta Ltd. , Prilaz baruna Filipovića 29, Zagreb, HR-10000, Croatia
| | - Jovica Ralic
- Fidelta Ltd. , Prilaz baruna Filipovića 29, Zagreb, HR-10000, Croatia
| | - Line Oste
- Galapagos NV , Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Reginald Brys
- Galapagos NV , Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Bertrand Heckmann
- Galapagos SASU , 102 Avenue Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
7
|
Čikoš A, Triballeau N, Hubbard PA, Žiher D, Stouten PFW, Doyon JGPO, Deschrijver T, Wouters J, Lépine RHM, Saniere L. Reinvestigation of the Branimycin Stereochemistry at Position 17-C. Org Lett 2016; 18:780-3. [DOI: 10.1021/acs.orglett.6b00044] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ana Čikoš
- Fidelta, Ltd., Prilaz
baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Nicolas Triballeau
- Galapagos SASU,
Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Paul A. Hubbard
- BioFocus DPI, Ltd., Chesterford Research
Park, Saffron Walden CB10
1XL, United Kingdom
| | - Dinko Žiher
- Fidelta, Ltd., Prilaz
baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Pieter F. W. Stouten
- Galapagos NV,
Industriepark Mechelen Noord, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Julien G. P.-O. Doyon
- Galapagos NV,
Industriepark Mechelen Noord, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Tiny Deschrijver
- Galapagos NV,
Industriepark Mechelen Noord, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium
| | - Johan Wouters
- Université de Namur ASBL, Rue de
Bruxelles 61, 5000 Namur, Belgium
| | - Renaud H. M. Lépine
- Galapagos SASU,
Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Laurent Saniere
- Galapagos SASU,
Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
8
|
Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E, Delerive P, Deprez P, De Vos S, Djata F, Fletcher S, Kopiejewski S, L’Ebraly C, Lefrançois JM, Lavazais S, Manioc M, Nelles L, Oste L, Polancec D, Quénéhen V, Soulas F, Triballeau N, van der Aar EM, Vandeghinste N, Wakselman E, Brys R, Saniere L. Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic. J Med Chem 2014; 57:10044-57. [DOI: 10.1021/jm5012885] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
| | - Sonia Dupont
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Marielle Babel
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | - Roland Blanqué
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Laëtitia Cherel
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | - Elsa De Lemos
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | - Pierre Deprez
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Steve De Vos
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Fatoumata Djata
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | | | | | | | - Murielle Manioc
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Luc Nelles
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Line Oste
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Denis Polancec
- Fidelta, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia
| | | | | | | | | | | | | | - Reginald Brys
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Laurent Saniere
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
9
|
Nique F, Hebbe S, Triballeau N, Peixoto C, Lefrançois JM, Jary H, Alvey L, Manioc M, Housseman C, Klaassen H, Van Beeck K, Guédin D, Namour F, Minet D, Van der Aar E, Feyen J, Fletcher S, Blanqué R, Robin-Jagerschmidt C, Deprez P. Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator. J Med Chem 2012; 55:8236-47. [PMID: 22957947 DOI: 10.1021/jm300281x] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Structural modification performed on a 4-methyl-4-(4-hydroxyphenyl)hydantoin series is described which resulted in the development of a new series of 4-(hydroxymethyl)diarylhydantoin analogues as potent, partial agonists of the human androgen receptor. This led to the identification of (S)-(-)-4-(4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile ((S)-(-)-18a, GLPG0492) evaluated in vivo in a classical model of orchidectomized rat. In this model, (-)-18a exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing. (-)-18a has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials.
Collapse
Affiliation(s)
- François Nique
- GALAPAGOS, Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Nique F, Hebbe S, Peixoto C, Annoot D, Lefrançois JM, Duval E, Michoux L, Triballeau N, Lemoullec JM, Mollat P, Thauvin M, Prangé T, Minet D, Clément-Lacroix P, Robin-Jagerschmidt C, Fleury D, Guédin D, Deprez P. Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators. J Med Chem 2012; 55:8225-35. [DOI: 10.1021/jm300249m] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- François Nique
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Séverine Hebbe
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Christophe Peixoto
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Denis Annoot
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Eric Duval
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Laurence Michoux
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Nicolas Triballeau
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Patrick Mollat
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Maxime Thauvin
- UMR 8015 CNRS, Université Paris Descartes, 4 Avenue de l’Observatoire,
75006 Paris, France
| | - Thierry Prangé
- UMR 8015 CNRS, Université Paris Descartes, 4 Avenue de l’Observatoire,
75006 Paris, France
| | - Dominique Minet
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | - Damien Fleury
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Denis Guédin
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Pierre Deprez
- GALAPAGOS, Parc
Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
11
|
Mony L, Triballeau N, Paoletti P, Acher FC, Bertrand HO. Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach. Bioorg Med Chem Lett 2010; 20:5552-8. [DOI: 10.1016/j.bmcl.2010.07.043] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2010] [Revised: 07/09/2010] [Accepted: 07/09/2010] [Indexed: 12/01/2022]
|
12
|
Pietrancosta N, Kessler A, Favre-Besse FC, Triballeau N, Quentin T, Giros B, El Mestikawy S, Acher FC. Rose Bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorg Med Chem 2010; 18:6922-33. [PMID: 20708942 DOI: 10.1016/j.bmc.2010.06.069] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Revised: 06/21/2010] [Accepted: 06/21/2010] [Indexed: 10/19/2022]
Abstract
Vesicular glutamate transporters (VGLUTs) allow the loading of presynaptic glutamate vesicles and thus play a critical role in glutamatergic synaptic transmission. Rose Bengal (RB) is the most potent known VGLUT inhibitor (Ki 25 nM); therefore we designed, synthesized and tested in brain preparations, a series of analogs based on this scaffold. We showed that among the two tautomers of RB, the carboxylic and not the lactonic form is active against VGLUTs and generated a pharmacophore model to determine the minimal structure requirements. We also tested RB specificity in other neurotransmitter uptake systems. RB proved to potently inhibit VMAT (Ki 64 nM) but weakly VACHT (Ki>9.7 microM) and may be a useful tool in glutamate/acetylcholine co-transmission studies.
Collapse
Affiliation(s)
- Nicolas Pietrancosta
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR8601 CNRS, Université Paris Descartes, 45 rue des Saints-Pères, 75270 Paris 06, France
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Selvam C, Oueslati N, Lemasson IA, Brabet I, Rigault D, Courtiol T, Cesarini S, Triballeau N, Bertrand HO, Goudet C, Pin JP, Acher FC. A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem 2010; 53:2797-813. [PMID: 20218620 DOI: 10.1021/jm901523t] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
(R)-PCEP (3-amino-3-carboxypropyl-2'-carboxyethyl phosphinic acid, 1), a new metabotropic glutamate receptor 4 (mGlu4R) agonist, was discovered in a previously reported virtual screening. The (S)-enantiomer and a series of derivatives were synthesized and tested on recombinant mGlu4 receptors. A large number of derivatives activated this receptor but was not able to discriminate between mGlu4 and mGlu8 receptors. The most potent ones 6 and 12 displayed an EC(50) of 1.0 +/- 0.2 microM at mGlu4R. Interestingly these agonists with longer alkyl chains revealed a new binding pocket adjacent to the glutamate binding site, which is lined with residues that differ among the mGluR subtypes and that will allow the design of more selective compounds. Additionally 6 was able to activate mGlu7 receptor with an EC(50) of 43 +/- 16 microM and is thus significantly more potent than L-AP4 (EC(50) of 249 +/- 106 microM).
Collapse
Affiliation(s)
- Chelliah Selvam
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Universite Paris Descartes, 45 Rue des Saints-Peres, 75270 Paris Cedex 06, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Triballeau N, Van Name E, Laslier G, Cai D, Paillard G, Sorensen PW, Hoffmann R, Bertrand HO, Ngai J, Acher FC. High-potency olfactory receptor agonists discovered by virtual high-throughput screening: molecular probes for receptor structure and olfactory function. Neuron 2009; 60:767-74. [PMID: 19081373 DOI: 10.1016/j.neuron.2008.11.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2008] [Revised: 11/03/2008] [Accepted: 11/10/2008] [Indexed: 11/27/2022]
Abstract
The detection of diverse chemical structures by the vertebrate olfactory system is accomplished by the recognition of odorous ligands by their cognate receptors. In the present study, we used computational screening to discover novel high-affinity agonists of an olfactory G protein-coupled receptor that recognizes amino acid ligands. Functional testing of the top candidates validated several agonists with potencies higher than any of the receptor's known natural ligands. Computational modeling revealed molecular interactions involved in ligand binding and further highlighted interactions that have been conserved in evolutionarily divergent amino acid receptors. Significantly, the top compounds display robust activities as odorants in vivo and include a natural product that may be used to signal the presence of bacteria in the environment. Our virtual screening approach should be applicable to the identification of new bioactive molecules for probing the structure of chemosensory receptors and the function of chemosensory systems in vivo.
Collapse
Affiliation(s)
- Nicolas Triballeau
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, CNRS UMR-8601, Université Paris Descartes, 45 rue des Saints Pères, 75270 Paris Cedex 06, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Frauli M, Hubert N, Schann S, Triballeau N, Bertrand HO, Acher F, Neuville P, Pin JP, Prézeau L. Amino-pyrrolidine tricarboxylic acids give new insight into group III metabotropic glutamate receptor activation mechanism. Mol Pharmacol 2006; 71:704-12. [PMID: 17167031 DOI: 10.1124/mol.106.030254] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Like most class C G-protein-coupled receptors, metabotropic glutamate (mGlu) receptors possess a large extracellular domain where orthosteric ligands bind. Crystal structures revealed that this domain, called Venus FlyTrap (VFT), adopts a closed or open conformation upon agonist or antagonist binding, respectively. We have described amino-pyrrolidine tricarboxylic acids (APTCs), including (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (FP0429), as new selective group III mGlu agonists. Whereas FP0429 is an almost full mGlu4 agonist, it is a weak and partial agonist of the closely related mGlu8 subtype. To get more insight into the activation mechanism of mGlu receptors, we aimed to elucidate why FP0429 behaves differently at these two highly homologous receptors by focusing on two residues within the binding site that differ between mGlu4 and mGlu8. Site-directed mutagenesis of Ser157 and Gly158 of mGlu4 into their mGlu8 homologs (Ala) turned FP0429 into a weak partial agonist. Conversely, introduction of Ser and Gly residues into mGlu8 increased FP0429 efficacy. Docking of FP0429 in mGlu4 VFT 3D model helped us characterize the role of each residue. Indeed, mGlu4 Ser157 seems to have an important role in FP0429 binding, whereas Gly158 may allow a deeper positioning of this agonist in the cavity of lobe I, thereby ensuring optimal interactions with lobe II residues in the fully closed state of the VFT. In contrast, the presence of a methyl group in mGlu8 (Ala instead of Gly) weakens the interactions with the lobe II residues. This probably results in a less stable or a partially closed form of the mGlu8 VFT, leading to partial receptor activation.
Collapse
|
16
|
|
17
|
Schann S, Menet C, Arvault P, Mercier G, Frauli M, Mayer S, Hubert N, Triballeau N, Bertrand HO, Acher F, Neuville P. Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): identification of a new group III metabotropic glutamate receptor selective agonist. Bioorg Med Chem Lett 2006; 16:4856-60. [PMID: 16828551 DOI: 10.1016/j.bmcl.2006.06.062] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Revised: 06/16/2006] [Accepted: 06/17/2006] [Indexed: 11/19/2022]
Abstract
A new family of mGlu receptor orthosteric ligands called APTCs was designed and synthesized using a parallel chemistry approach. Amongst 65 molecules tested on mGlu4, mGlu6 and mGlu8 subtypes, (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (8a06-FP0429) has been shown to be a full mGlu4 agonist and a partial mGlu8 agonist. In addition, 8a06 was shown to be selective versus group I and II mGlu subtypes. A possible explanation for this efficacy difference is proposed by docking experiment performed with molecular model of the receptor.
Collapse
Affiliation(s)
- Stephan Schann
- Faust Pharmaceuticals, BIOPARC, Boulevard Sebastien Brant, 67400 Illkirch, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO. Virtual Screening Workflow Development Guided by the “Receiver Operating Characteristic” Curve Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor Subtype 4. J Med Chem 2005; 48:2534-47. [PMID: 15801843 DOI: 10.1021/jm049092j] [Citation(s) in RCA: 458] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The "receiver operating characteristic" (ROC) curve method is a well-recognized metric used as an objective way to evaluate the ability of a given test to discriminate between two populations. This facilitates decision-making in a plethora of fields in which a wrong judgment may have serious consequences including clinical diagnosis, public safety, travel security, and economic strategies. When virtual screening is used to speed-up the drug discovery process in pharmaceutical research, taking the right decision upon selecting or discarding a molecule prior to in vitro evaluation is of paramount importance. Characterizing both the ability of a virtual screening workflow to select active molecules and the ability to discard inactive ones, the ROC curve approach is well suited for this critical decision gate. As a case study, the first virtual screening workflow focused on metabotropic glutamate receptor subtype 4 (mGlu4R) agonists is reported here. Six compounds out of 38 selected and tested in vitro were shown to have agonist activity on this target of therapeutic interest.
Collapse
Affiliation(s)
- Nicolas Triballeau
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR8601-CNRS, Université René Descartes-Paris V, 75270 Paris Cedex 06, France.
| | | | | | | | | |
Collapse
|
19
|
Bessis AS, Rondard P, Gaven F, Brabet I, Triballeau N, Prezeau L, Acher F, Pin JP. Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proc Natl Acad Sci U S A 2002; 99:11097-102. [PMID: 12151600 PMCID: PMC123216 DOI: 10.1073/pnas.162138699] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2002] [Indexed: 11/18/2022] Open
Abstract
Ca2+, pheromones, sweet taste compounds, and the main neurotransmitters glutamate and gamma-aminobutyric acid activate G protein-coupled receptors (GPCRs) that constitute the GPCR family 3. These receptors are dimers, and each subunit has a large extracellular domain called a Venus flytrap module (VFTM), where agonists bind. This module is connected to a heptahelical domain that activates G proteins. Recently, the structure of the dimer of mGlu1 VFTMs revealed two important conformational changes resulting from glutamate binding. First, agonists can stabilize a closed state of at least one VFTM in the dimer. Second, the relative orientation of the two VFTMs in the dimer is different in the presence of glutamate, such that their C-terminal ends (which are connected to the G protein-activating heptahelical domain) become closer by more than 20 A. This latter change in orientation has been proposed to play a key role in receptor activation. To elucidate the respective role of VFTM closure and the change in orientation of the VFTMs in family 3 GPCR activation, we analyzed the mechanism of action of the mGlu8 receptor antagonists ACPT-II and MAP4. Molecular modeling studies suggest that these two compounds prevent the closure of the mGlu8 VFTM because of ionic and steric hindrance, respectively. We show here that the replacement of the residues responsible for these hindrances (Asp-309 and Tyr-227, respectively) by Ala allows ACPT-II or MAP4 to fully activate the receptors. These data are consistent with the requirement of the VFTM closure for family 3 GPCR activation.
Collapse
Affiliation(s)
- Anne-Sophie Bessis
- Départment de Chimie et Biochimie Pharmacologiques et Toxicologiques, Unité Mixte de Recherche 8601-Centre National de la Recherche Scientifique, Université René Descartes-Paris V, 45 Rue des Saints-Pères, 75270 Paris Cedex 06, France
| | | | | | | | | | | | | | | |
Collapse
|